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Abstract: Nitric oxide synthase (NOS) plays important roles within the cardiovascular system
in physiological states as well as in pathophysiologic and specific cardiovascular (CV) disease
states, such as hypertension (HTN), arteriosclerosis, and cerebrovascular accidents. This review
discusses the roles of the endothelial NOS (eNOS) and its effect on cardiovascular responses that
are induced by nociceptive stimuli. The roles of eNOS enzyme in modulating CV functions while
experiencing pain will be discussed. Nociception, otherwise known as the subjective experience
of pain through sensory receptors, termed “nociceptors”, can be stimulated by various external
or internal stimuli. In turn, events of various cascade pathways implicating eNOS contribute to a
plethora of pathophysiological responses to the noxious pain stimuli. Nociception pathways involve
various regions of the brain and spinal cord, including the dorsolateral periaqueductal gray matter
(PAG), rostral ventrolateral medulla (RVLM), caudal ventrolateral medulla, and intermediolateral
column of the spinal cord. These pathways can interrelate in nociceptive responses to pain stimuli.
The alterations in CV responses that affect GABAergic and glutamatergic pathways will be discussed
in relation to mechanical and thermal (heat and cold) stimuli. Overall, this paper will discuss the
aggregate recent and past data regarding pain pathways and the CV system.
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1. Introduction
Endothelial nitric oxide synthase (eNOS) is one of the isoforms of nitric oxide synthase
(NOS). Endothelial NOS is highly expressed in vascular endothelial cells. The biochemical
reaction to produce nitric oxide is shown below:
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emotional experience that is accompanied by some degree of tissue damage. Stimuli of a
painful nature may result from different inputs including mechanical, chemical, or thermal
origins. Mechanical responses include injury such as a laceration to the skin [5], while
chemical stimuli may include events such as exposure to a “hot” gustatory stimulus, such
as capsaicin, on the tongue [6]. In addition, thermal stimuli include contact with extreme

Molecules 2022, 27, 2835

3 of 14

heat or extreme cold [7]. These phenomena may stimulate sensory pain receptors that will
relay signals to different areas of the brain via afferent fibers in the peripheral and central
nervous system. These signals are integrated by sensory integration centers involving the
medulla oblongata, periaqueductal gray matter (PAG), hypothalamus, and thalamus [8].
The aforementioned relay pathways are relevant to the physiological role played by eNOS.
Stimulation of nociceptors may activate the eNOS pathway via autonomic nervous systemmediated inflammation and vasodilation cascades [9]. The CVS plays a significant role in
the appropriate execution of such cascades. Accordingly, we will discuss these pathways in
depth, including the function of eNOS in relation to CV pathologies, such as hypertension
and atherosclerosis.
1.2. Cardiovascular System
The CV system is a complex arrangement of arteries, capillaries, veins, and a central
organ or the heart that works systematically to circulate blood throughout the body. It is
a critical system that drives the transportation of vital resources and signals to different
areas in the body, including oxygen, carbon dioxide, vitamins, minerals, neurotransmitters
(for platelet aggregation), insulin, and NO [10]. The eNOS isoenzyme can interact with
the cardiovascular system by regulating signal relay and resource allocation. However,
the exact mechanism delineating this relationship with nociception remains unknown.
For example, reduced function or bioavailability of the eNOS isoenzyme is linked to
increased risk of essential hypertension, preeclampsia, diabetic nephropathy, retinopathy,
migraine, and erectile dysfunction in humans [11]. As noted, reduced eNOS expression
produces several deleterious effects; however, eNOS upregulation can result in homeostatic
dysregulation as well [12]. Overexpression in the rostral ventrolateral medulla (RVLM) is
positively correlated with hypotension and bradycardia. Both pathologies are preceded by
altered neurotransmitter levels, namely increased levels of inhibitory gamma amino-butyric
acid (GABA) and decreased levels of excitatory glutamate [12]. Upregulation of eNOS may
be a result of stress caused by the release of acetylcholine (ACh), bradykinin, histamine,
and 17β-estradiol-mediated phosphorylation [13]. The following sections will describe
and present the scientific literature that is pertinent to the complex relationships among
nociception, CVS, and NO.
2. Endothelial Nitric Oxide Synthase and Nociception
Nociception, or more commonly known as pain, is a sensation that also involves an
emotional component. The International Association for the Study of Pain (IASP9) offers the
following definition of pain: “An unpleasant sensory and emotional experience associated
with actual or potential tissue damage or described in terms of such damage” [14]. We
have previously published an extensive review regarding the role of nNOS isoform on CV
responses elicited during mechanically, heat-, and cold-induced changes in mean arterial
pressure (MAP) and heart rate (HR) using a model of anesthetized rat [9]. Briefly, the
alterations in CV responses due to pain are dependent on the type of pain, intensity of
pain, involvement of specific nociceptors, neural pathways, and the involvement of various
neurotransmitters or receptors [15]. It has been widely studied that the eNOS system
interacts with the ventrolateral medullar (VLM) and PAG to modulate pain. Moreover,
several brain regions such as the RVLM, the caudal ventrolateral medulla (CVLM), and the
dorsolateral periaqueductal gray matter (dlPAG) play differential roles in integrating and
modulating CV responses during pain [13]. Manipulating NO concentrations within the
dlPAG or medulla oblongata affects the glutamatergic and GABAergic pathways during
nociceptive experiences triggered by thermal (heat/cold) stimuli but not mechanical stimuli
or pinch/pressure [16]. Past studies demonstrate that dysregulation of all NOS isoforms
(nNOS, eNOS, inducible NOS (iNOS)) can significantly alter the experience of pain. For
example, overproduction of NO by all NOS isoforms may result in neuroprotective or
neurotoxic impacts mediated through the generation of reactive oxygen waste products
(peroxynitrite) [17]. Subsequent chain reactions with carbon dioxide (CO2 ) can induce
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Figure 2. Mechanism of how initial tissue injury leads to pain reduction through activation of eNOS,
production of nitric oxide (NO), and increase in cGMP. eNOS is stimulated in vascular endothelia
by tissue injury, such as knee injury, skin laceration, and wounds. NO, which is produced by eNOS,
diffuses to the vascular smooth muscle cells. Upon stimulation by NO, guanylate cyclase converts
GTP to cGMP, resulting in vascular smooth muscle relaxation. Vasodilation has been shown to be
associated with pain reduction, possibly through reduced inflammation and increased angiogenesis.

Using a chronic constriction injury (CCI) rat model, Chu et al. showed that atorvastatin, a cholesterol-lowering drug, could reduce nociceptive sensitization and thermal
hyperalgesia of peripheral neuropathy. It improved the inflammatory activity through
reductions in cyclooxygenase-2 (COX-2) and iNOS. In addition, atorvastatin also increased
neuroprotective factors that elicit positive responses in angiogenesis, including eNOS, vascular endothelial growth factor (VEGF), and (phosphorylated) protein kinase B (pAkt/Akt).
However, this angiogenic property was not observed in eNOS knock-out mice, suggesting
the importance of the eNOS-associated signal cascade in promoting vascular growth during
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Thus, reduced NO is conceivably tied to vaso-occlusive pain and nociceptive processing.
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Herein, the reduced bioavailability of arginine in such patients is linked with experiences
of acute pain, vaso-occlusive pain, endothelial dysfunction, pulmonary complications, risk
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pain,
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dysfunction,
pulmonary
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[29].endothelial
However, the
specific mechanism
remains
unclear, as
other studies corroborate increased pain in association with elevated levels of arginine [30].
Individuals carrying the thymine-cytosine and cytosine-cytosine (TC/CC) genotypes
and the C allele for the g.-786T > C polymorphisms (eNOS) were more likely to respond
better to enalapril, an angiotensin-converting enzyme (ACE) inhibitor. The polymorphism
may be responsible for a more robust NO production, conferring the individuals a better
response to the antihypertensive drug [31]. Peroxisome proliferator-activated receptor
gamma coactivator-1alpha (PGC-1α) has also been shown to enhance NO production
and reduce blood pressure. However, it increased NO production not by altering eNOS
expression, but by inhibiting the uncoupling of eNOS dimers [32].
Several studies aim to explore the roles of transient receptor potential vanilloid type 1
(TRPV1) on NOS activation and its subsequent downstream effects of CV-specific angiogenesis in primary nociceptive sensory neurons. TRPV1 is mainly distributed throughout
vascular endothelial cells, smooth muscle cells, and perivascular nerve cells in the cardiovascular system. It is responsive to inflammatory and noxious stimuli and can serve as
a blood pressure mechanoreceptor within vasculature [33]. In addition, NO-dependent
processes as a result of TRPV1 stimulation are a vital facet in the creation of new blood
vessels and wound-healing, two factors that are important in countering the effects of
cardiovascular disease such as arteriosclerosis or ischemic heart disease [34]. Activation of
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TRPV1 in endothelial cells promotes Ca2+ -dependent signaling of phosphatidylinositol-3kinase (PI3K), Akt, and Ca2+ /calmodulin-dependent protein kinase II (CaMKII), which
subsequently leads to increases in TRPV1-eNOS complex formation, eNOS activation, and
NO production. eNOS and TRPV1 knockouts displayed reduced angiogenesis, increased
atherosclerotic lesions, and reduced phosphorylation of eNOS and Akt [35].
Previously, it has been shown that the reduced atherosclerosis through uncoupling activity results in reduction of NO [13]. Studies explore oxidized low-density lipoprotein (OxLDL) as a cytotoxic agent that can impair endothelial cells and exacerbate the progression
of atherosclerosis. This mechanism is an advancement of oxLDL-mediated inflammation
that consequently decreases peroxisome proliferator-activated receptor gamma (PPARγ)
endothelium protection, a factor that typically participates in eNOS expression through
AMP-activated protein kinase (AMPK) and lectin-like oxidized low-density lipoprotein
receptor-1 (LOX-1) signal cascades [36]. Inactivation of this pathway can cause detrimental
fluctuation of atherosclerotic plaques and vascular malfunction.
Sildenafil (Viagra® , Revatio® ) is a phosphodiesterase type 5 inhibitor (PDE5 inhibitor)
that induces vasodilation by preventing PDE5 from degrading cGMP. Sildenafil exerts its
neuroprotective effect by inhibiting inflammation and demyelination in the cerebellum [37].
Sildenafil was capable of decreasing the expression of the pro-inflammatory cytokines
interleukin-1-beta (IL-1β) and tumor necrosis factor alpha (TNF-α); decreasing glial fibrillation acidic protein (GFAP), nuclear factor kappa light chain enhancer of active B-cells
(NFkB), inactive AMPK, iNOS; and increasing the anti-inflammatory cytokine IL-10 and nuclear factor alpha of kappa light polypeptide gene enhancer in B-cell inhibitor (IKβα) [37].
Based on this discovery, sildenafil likely induces its anti-inflammatory and neuroprotective
effects through the modulation of AMPK–IKβα–NFκB signaling [37].
4. Interaction between Endothelial Nitric Oxide Synthase, Nociception, and the
Cardiovascular System
Major inflammatory responses are due to an elevation of microvascular permeability
for numerous chemicals, particularly macromolecules, which result in the manifestations
of edema. An increase in edema may cause disturbed homeostasis and tissue dysfunction,
especially in the endothelium of venules. As mentioned previously, NO is physiologically
known to be an important signaling regulator of cardiovascular function, particularly the
significance of its role in the control of microvascular permeability [38,39]. Experiments
using isolated venules, single capillaries, and endothelial cells of eNOS knockout mice
have demonstrated that increased eNOS activities will elevate microvascular permeability
to macromolecules that may happen due to inflammatory responses or medications [40,41].
Definitive evidence to settle this initial controversy was obtained. Studies using engineered
animals determine eNOS-derived NO causes hyperpermeability due to pro-inflammatory
agents such as platelet-activating factor (PAF) and vascular endothelial growth factor
(VEGF) both in vivo and in vitro [42,43]. The signaling cascades for several inflammatory
agents or conditions also require the activation of protein kinase C (PKC) and eNOS, which
are followed by synthesis of cGMP [44,45]. Finally, studies using isolated micro-blood
vessels would show that stimulation of eNOS and subsequent production of cGMP leads to
changes in permeability to both major and minor molecules (small and large solutes) [46].
Further physiological, pathophysiological, and molecular biology investigations will contribute to higher understanding of the knowledge that controls microvascular mechanism
and will lead to the development of pharmacologic agents and treatment for systemic
inflammation. The relationship among eNOS, CVS, and the CNS are previously mentioned
in our recent review [13].
There have been more than 45 million studies that have focused on CVD and reduced
eNOS activity. In short, various CVD risk factors such as hypertension, diabetes, insulin
resistance, obesity and hyperlipidemia are because of reduced eNOS dysfunction [47]. It has
been recognized that the eNOS mechanism of endothelial function is the prevention against
atherogenesis cascades, such as vascular smooth muscle cell proliferation, inflammation, or
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thrombosis. As reported, eNOS dysfunction at a reduced production does not protect the
normal physiologic and protective mechanisms of the endothelial cells [48,49], for example,
if the endothelium is damaged with reduced eNOS, particularly for damaged endothelium
and eNOS in coronary arteries subjected to angioplasty or percutaneous intervention, and
metabolic toxins, such as free fatty acids (FFAs) and inflammatory cytokines, including
IL-6 and TNF-α. Patients with hyperglycemia can also have advanced glycation products
and other metabolic abnormalities that may affect eNOS-mediated intracellular signaling
pathways; even the PI3K–Akt pathway and Akt downstream to PI3K that is inhibited by
ipatasertib. In addition, any ROS can destroy vascular eNOS and prevent it from inducing
vascular smooth muscle relaxation [50,51].
Regarding the drugs that are developed to modulate pain pathways, there have
been more than 73 thousand research publications. In short, normal regulatory mechanisms of eNOS activity, such as calcium/calmodulin, caveolin, HSP90, palmitoylation, and
myristoylation, can activate phosphorylation by AKT or AMP-activated protein kinase
(AMPK) at Serine 1177. Other regulations of eNOS activity are based on the formation
of redox-active species that cause dysfunctional phosphorylation by redox-active kinases
at Thr495/Tyr657 [52,53]. REDOX alterations in eNOS disrupt eNOS activity and uncouple eNOS [52]. In addition, cGMP-degrading phosphodiesterases are activated by
ROS [54,55]. Any changes of prostanoid synthesis/production to thromboxane can result
in vasoconstriction and aggregatory phenotype [52].
Previously, we have reported that mechanically induced and heat-mediated thermal
pain increase MAP and HR, while a cold-evoked thermal pain stimulus causes decreases
in MAP and HR [56–59]. Although the link between the cardiovascular and nociceptive
systems has been extensively studied, the precise mechanisms within the human brain
that regulate this relationship are still unknown. Particularly, the plethora of diverse
mechanisms, the interaction of numerous neurotransmitters/neuromodulators, specific
regions of the brain, interaction among receptors, and different management or treatment
protocols make the field of nociception research vast and more complex. Nevertheless,
the CVS and nociception are interrelated and are displayed quite significantly by bodily
homeostasis and defensive/withdrawal reactions including changes in cardiovascular
hemodynamics. We have written a chapter in a book that describes numerous pain therapies
that are prescribed for treatment of different variations of peripheral neuropathic pain
in humans, including their side effects or toxicology on cardiovascular functions and the
CVS [57].
As mentioned, NO levels within the medulla oblongata or the dlPAG differentially
modulate cardiovascular responses by altering glutamatergic and GABAergic neurotransmission during heat-induced, but not in response to mechanically induced nociceptive
stimulation. One such example is that nNOS antagonism within the dlPAG potentiates cardiovascular responses during heat-induced thermal stimulation via increasing glutamate
release and reducing GABA levels. nNOS, however, does not alter those cardiovascular responses and neurotransmission during mechanical nociception. Many reviews and studies
using humans and animals demonstrate that NO, eNOS, iNOS, and nNOS play significant
roles in neuronal excitability through a plethora of NO-related mechanisms involving nociception, particularly the eNOS protein and neuropathic pain [60]. A 2007 study compared
the reactions to pain following intraplantar injection of CFA in wild-type (WT) and eNOSdeficient mice. The study found significant changes in the behavior reaction to pain in
eNOS-deficient mice, including a rapid recovery from thermal hyperalgesia [61]. The first
clinical trial that attempted to block all three NOS by using a non-selective NOS inhibitor,
L-NG-methylarginine hydrochloride (546C88), shows that 546C88 is an effective drug for
headache relief and can also improve the symptoms of sensory hypersensitivity [62]. Another human trial shows that the non-selective NOS inhibitor, NG-monomethyl-L-arginine
hydrochloride (L-NMMA), provides significant relief from pain in patients with chronic
tension-type headache [63]. Although eNOS has a role in the pathogenesis of migraine, not
many clinical studies have been conducted for drug research and discovery because of its
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high potential of interference with the CVS. Therefore, our laboratory uses rat models to
study the role of eNOS within specific regions of the brain on cardiovascular responses
elicited by pain. We have investigated the effects of eNOS blockade within the dlPAG
on cardiovascular responses and neurotransmission during mechanical, heat, and cold
nociception. Our results show that eNOS antagonism within the dlPAG augments cardiovascular responses during heat-induced thermal stimulation [64]. In contrast, antagonism
of eNOS activity plays no role in modulating cardiovascular responses during mechanical
nociception, and surprisingly, cold-induced thermal stimuli evoke depressor and bradyresponses
that were reversed by the blockade of eNOS within the dlPAG [64]. The
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Our data provide further insight into the interactions between nociceptive pathways
and the CVS involving the eNOS protein within the dlPAG. However, future research
using specific NOS isoform agonists or antagonists should continue for the development of
potential therapeutic agents for the treatment of neuropathic and other pain with minimal
effects on the CVS. To sum it all, there is an old adage that says: “No pain, no gain”, which is
why we still do not know the exact mechanisms, pain pathways, neurotransmitters, and
medications that are relevant to nociception.
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This review elaborates on the past and present discoveries regarding the complex
relationships of eNOS isozymes, CVS, and nociception. The following are the highlights of
our review:
1.
2.
3.
4.
5.
6.

The presence of eNOS in dorsal root ganglia and other nervous tissues has been
shown to play a role in nociception.
The eNOS pathway can be activated by the stimulation of nociceptors.
Through its vasodilatory effect, eNOS may affect nociception by regulating the movement of important mediators across the blood vessel walls.
Endothelial NOS have pro- or anti-nociceptive effects.
Endothelial NOS can also affect nociception through its formation of peroxynitrite
and its interaction with TRPV1 as well as with pro- and anti-inflammatory mediators.
MAP and HR are both altered during mechanically, heat- and cold-induced nociception. Inhibition of eNOS in PAG affects MAP and HR responses to heat- and cold- but
not to mechanical-induced nociception.
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neurotransmission. Furthermore, NO derived from eNOS within the dlPAG has a potential
impact on attenuating the cardiovascular responses during heat-induced nociception, but
not mechanically or cold-induced nociception. However, we have not examined the correlations of eNOS activity levels and the aforementioned nociceptive-triggered cardiovascular
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responses. A closer investigation of these correlations may provide us with a better drug
development approach in targeting eNOS to reduce pain, particularly in determining the
proper dosage amount to achieve the therapeutic effects and avoid the adverse effects.
The supposedly contradictory effects of nitric oxide in nociceptive pathways, namely
the mechanisms that allow for both pro-nociceptive and anti-nociceptive outputs, have
been delineated in several scientific studies that aim to explain the disparity [65]. This may
be explained by a duality in eNOS function, where it plays a neuroprotective role in earlier
stages of ischemia or shear stress versus a neurotrophic role in later stages [3]. In conclusion,
this review discusses many roles of eNOS in both physiological and pathological states
of the CVS that are related to the eNOS inflammation cascade during experiences of
nociception. Moreover, we extensively discuss the interrelated relationship between eNOS,
the CVS, and the CNS. We explain the pathogenesis of several cardiovascular diseases, such
as hypertension and atherosclerosis, that may happen because of disrupted eNOS activity.
We also review the function of eNOS during nociception and how several pharmaceutical
products, such as enalapril, atorvastatin, and L-NG-methylarginine hydrochloride (546C88),
may modulate the pain pathways.
The management of pain remains a major clinical challenge. A gradual loss in effectiveness after repeated use of opioid drugs, a phenomenon known as opioid tolerance, often
develops along with physical dependence. The use of adjuvant non-opioid, particularly
ketamine, is known to reduce tolerance and physical dependence. The multimodal approach to pain management, i.e., combining multiple agents from different drug classes, has
become increasingly more favorable [66]. Other drugs that can be used in the multimodal
approach of pain management include non-steroidal anti-inflammatory drugs (NSAIDs),
gabapentinoids, acetaminophen, local anesthetics, and α2 agonists. The discoveries of
novel non-opioid adjuvants will undoubtedly help mitigate the epidemic of the opioid
crisis [67]. Therefore, future research should be geared toward developing novel analgesic
agents that target eNOS without significant adverse reactions. These adverse reactions will
likely be related to the effects of eNOS on CVS. Our review provides a unique perspective
of how eNOS may serve as a potential analgesic target through its complex interaction with
nociception and CVS.
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